Manufactures nucleic acids products for research and vaccine programs.
Jun 2026Revenue $209M/yrExpenses $326M/yr
Fell below break-even Dec 2023Cash runway ≈ 2.0 years from Jun 2026
Figures by year
When will Maravai Lifesciences Holdings be profitable again?
Its expenses passed its revenue in Dec 2023. In the 12 months to Jun 2026, revenue was $209M and expenses $326M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $186M | $401M | −$215M |
| Dec 2024 | $259M | $495M | −$236M |
| Dec 2023 | $289M | $321M | −$31.6M |
| Dec 2022 | $883M | $309M | $574M |
| Dec 2021 | $799M | $245M | $555M |
| Dec 2020 | $284M | $164M | $120M |
| Dec 2019 | $143M | $119M | $24.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.